Lung cancer is the leading cause of cancer death worldwide. Majority of newly diagnosed
lung cancers are non-small cell lung cancer (NSCLC), of which up to half are considered …

Objectives Stage III non-small cell lung cancer (NSCLC) describes a heterogeneous
population with disease presentation ranging from apparently resectable tumors with occult …

Systemic therapy should be considered in patients with advanced non–small cell lung
cancer (NSCLC) who are no longer amenable to local therapies. Systemic therapy has been …

Lung cancer is the second-most commonly diagnosed cancer and the leading cause of
cancer death worldwide. The most common histological type is non-small-cell lung cancer …

Background Stage IV non-small cell lung cancer (NSCLC) is a treatable, but not curable,
clinical entity in patients given the diagnosis at a time when their performance status (PS) …

Objective To develop evidence-based guidelines on best available treatment options for
patients with stage IIIB non-small cell lung cancer (NSCLC). Methods A review was …

For stage III non-small cell lung cancer (NSCLC), approximately a third of patients survive up
to 5 years, with decreasing 5-year survival rates for stage IIIB and stage IIIC disease …

The American Joint Committee on Cancer defines stage I non-small cell lung carcinoma
(NSCLC) as consisting of patients with a T1 or T2 primary tumor designation and no …

Stage IV non-small cell lung cancer (NSCLC) denotes the presence of metastatic disease
and is largely incurable using present-day therapies. Chemotherapy remains a therapeutic …

PURPOSE To provide evidence-based recommendations to practicing clinicians on
management of patients with stage III non–small-cell lung cancer (NSCLC). METHODS An …